Study Group: Oncologists who Treat RCC (US)
Council Members in this Study Group: 47
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Donald FlemingDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...
Taral PatelOncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...
Al BarqawiAssistant Professor
University of Colorado Health Sciences Center - CCAl Barqawi, MD, FRCS, is Assistant Professor and Lecturer in the Division of Urology at University of Colorado Health Science Center. Dr. Barqawi also serves as Director of Research in the Section of Urologic Oncology. He has expertise in urologic oncology...
Eric WhitmanMedical Director, Office of Grants and Research
ATLANTIC HEALTH SYSTEM INCEric Whitman, MD, is the Medical Director of the Office of Grants and Research for Atlantic Health System in Morristown, New Jersey. He is a board certified General Surgeon with fellowship training in surgical oncology. He specializes in melanoma care,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 14, 2009
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
-
Synta Drug for Metastatic Melanoma Not Dead Yet (?)
November 3, 2009
Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com
Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated analysis suggests that a commonly available biomarker may identify patients who appear to benefit from Elesclomol treatment.This news is important because it may allow Synta to continue to pursue approval for Elesclomol in either melanoma patients or in other cancers. They will report an updated survival analysis twelve months after the protocol was stopped, after February 2010. Further info from Synta is expected soon.
-
Delcath Phase III trial for metastatic melanoma completes enrollment
November 3, 2009
Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com
The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submission.
-
Plexxikon Drug for Melanoma Continues to Show Great Promise
October 14, 2009
Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com
The new drug PLX-4032, being developed by Plexxikon and Roche, continues to show impressive short term results in melanoma patients with specific BRAF mutations, with a reported 70% tumor response rate.
-
Triple negative Breast Cancer Strategies
October 14, 2009
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Other Freestanding Healthcare Facility
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Partner
- Physician - Division Head
- President
- Owner
- Medical Director